Table 1: Multivariate cox regression analysis of 72 patients with MCL who have undergone autoSCT

From: Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma

 PFS from autoSCTOS from autoSCT
 PHRPHR
Rituximab maintenance0.020.23 (0.06–0.80)0.510.61 (0.14–2.65)
Year of transplant (beginning from 2000)0.790.97 (0.83–1.14)0.430.90 (0.69–1.16)
Age (per 10 years)0.961.00 (0.95–1.05)0.291.51 (0.69–3.30)
Remission prior autoSCT (non-CR vs CR)0.241.58 (0.73–3.47)0.411.64 (0.51–5.26)
HD-ARA treatment0.630.69 (0.16–3.12)0.960.94 (0.08–11.1)
Upfront autoSCT0.800.81 (0.17–3.97)0.720.64 (0.05–7.75)
  1. Abbreviations: autoSCT, autologous stem cell transplantation; CR, complete response; HR, hazard ratio; MCL, Mantle cell lymphoma; OS, overall survival; PFS, progression-free survival.
  2. Twenty-two patients received rituximab maintenance and 50 patients did not receive any further treatment.